Credit Suisse Group Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $114.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its target price lifted by research analysts at Credit Suisse Group from $101.00 to $114.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. Credit Suisse Group’s target price would suggest a potential downside of 4.31% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on SRPT. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $162.00 to $158.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. StockNews.com started coverage on shares of Sarepta Therapeutics in a research note on Wednesday, October 12th. They set a “hold” rating for the company. SVB Leerink raised their price target on shares of Sarepta Therapeutics from $126.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, October 17th. BTIG Research raised their price target on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, December 22nd. Finally, UBS Group upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $100.00 to $158.00 in a research note on Friday, December 16th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $150.92.

Sarepta Therapeutics Stock Up 1.4 %

NASDAQ SRPT opened at $119.13 on Tuesday. The company has a debt-to-equity ratio of 3.58, a quick ratio of 3.99 and a current ratio of 4.36. The firm has a 50-day simple moving average of $118.63 and a 200 day simple moving average of $108.06. Sarepta Therapeutics has a twelve month low of $61.28 and a twelve month high of $134.08. The stock has a market cap of $10.46 billion, a PE ratio of -14.51 and a beta of 1.04.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($1.73). Sarepta Therapeutics had a negative net margin of 81.76% and a negative return on equity of 97.37%. The company had revenue of $230.30 million during the quarter, compared to the consensus estimate of $234.55 million. During the same quarter in the previous year, the business posted ($0.60) EPS. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. On average, research analysts forecast that Sarepta Therapeutics will post -8.22 EPS for the current year.

Insider Activity

In related news, Director Stephen Mayo sold 858 shares of the firm’s stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $109.92, for a total value of $94,311.36. Following the completion of the sale, the director now owns 6,387 shares of the company’s stock, valued at $702,059.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FourThought Financial LLC increased its holdings in shares of Sarepta Therapeutics by 43.5% in the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares in the last quarter. Utah Retirement Systems grew its holdings in Sarepta Therapeutics by 0.7% during the 3rd quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company’s stock worth $1,654,000 after acquiring an additional 100 shares during the period. Neuberger Berman Group LLC grew its holdings in Sarepta Therapeutics by 2.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock worth $470,000 after acquiring an additional 105 shares during the period. Captrust Financial Advisors grew its holdings in Sarepta Therapeutics by 3.1% during the 2nd quarter. Captrust Financial Advisors now owns 3,534 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 107 shares during the period. Finally, Benchmark Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 2.9% during the 3rd quarter. Benchmark Investment Advisors LLC now owns 3,883 shares of the biotechnology company’s stock worth $429,000 after acquiring an additional 110 shares during the period. Institutional investors and hedge funds own 87.31% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.